Muscarinic Agonists – Talk Bio

Actionable Insights Powered by AI

Big Pharma-Backed MapLight Plots IPO to Advance Neuro Pipeline

1 month ago talkbio0Tagged Alzheimer 's disease psychosis, Biological Factors, Clinical Trials, IPO, MapLight Therapeutics, Morgan Stanley, Muscarinic Agonists, neuro pipeline, Schizophrenia, Series D financing

MapLight Therapeutics; IPO; neuro pipeline; Alzheimer’s disease psychosis; schizophrenia; M1/M4 muscarinic agonist; Series D financing; Morgan Stanley; biopharmaceutical; clinical trials

BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis

1 year ago talkbio0Tagged Alzheimer's Disease, Approved, KarXT, Mechanism (attribute), Muscarinic Agonists, Myers, Psychotic Disorders, Schizophrenia, squibb, United States Food and Drug Administration

KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.